161 related articles for article (PubMed ID: 21240490)
1. Long-term response after 6-year treatment with anakinra and onset of focal bone erosion in neonatal-onset multisystem inflammatory disease (NOMID/CINCA).
Rigante D; Leone A; Marrocco R; Laino ME; Stabile A
Rheumatol Int; 2011 Dec; 31(12):1661-4. PubMed ID: 21240490
[TBL] [Abstract][Full Text] [Related]
2. Neonatal treatment of CINCA syndrome.
Paccaud Y; Berthet G; Von Scheven-Gête A; Vaudaux B; Mivelaz Y; Hofer M; Roth-Kleiner M
Pediatr Rheumatol Online J; 2014; 12():52. PubMed ID: 25584041
[TBL] [Abstract][Full Text] [Related]
3. Current status of understanding the pathogenesis and management of patients with NOMID/CINCA.
Goldbach-Mansky R
Curr Rheumatol Rep; 2011 Apr; 13(2):123-31. PubMed ID: 21538043
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.
Neven B; Marvillet I; Terrada C; Ferster A; Boddaert N; Couloignier V; Pinto G; Pagnier A; Bodemer C; Bodaghi B; Tardieu M; Prieur AM; Quartier P
Arthritis Rheum; 2010 Jan; 62(1):258-67. PubMed ID: 20039428
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment with anakinra and canakinumab resolves patellar subchondral erosion in neonatal-onset multisystem inflammatory disease.
Leone A; Manna R; Verrecchia E; Cipullo M; Rigante D
Reumatismo; 2019 Apr; 71(1):53-55. PubMed ID: 30932446
[TBL] [Abstract][Full Text] [Related]
6. [Cryopyrin-associated periodic syndromes].
Quartier P; Rodrigues F; Georgin-Lavialle S
Rev Med Interne; 2018 Apr; 39(4):287-296. PubMed ID: 29111302
[TBL] [Abstract][Full Text] [Related]
7. Successful Treatment of CINCA/NOMID Syndrome with Interleukin-1 Blockade.
Macejová Z; Vargová V; Matejka M; Szekanecz Z
Isr Med Assoc J; 2015 Jun; 17(6):389-91. PubMed ID: 26234003
[No Abstract] [Full Text] [Related]
8. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes.
Sibley CH; Plass N; Snow J; Wiggs EA; Brewer CC; King KA; Zalewski C; Kim HJ; Bishop R; Hill S; Paul SM; Kicker P; Phillips Z; Dolan JG; Widemann B; Jayaprakash N; Pucino F; Stone DL; Chapelle D; Snyder C; Butman JA; Wesley R; Goldbach-Mansky R
Arthritis Rheum; 2012 Jul; 64(7):2375-86. PubMed ID: 22294344
[TBL] [Abstract][Full Text] [Related]
9. Muckle-Wells treatment with anakinra.
Eungdamrong J; Boyd KP; Meehan SA; Latkowski JA
Dermatol Online J; 2013 Dec; 19(12):20720. PubMed ID: 24365011
[TBL] [Abstract][Full Text] [Related]
10. Neonatal urticaria: Could it be CAPS?
Cutts L; Parslew R; Eustace K
Pediatr Dermatol; 2018 Nov; 35(6):e420-e421. PubMed ID: 30187963
[TBL] [Abstract][Full Text] [Related]
11. Post-inflammatory retinal dystrophy in CINCA syndrome.
Rigante D; Stabile A; Minnella A; Avallone L; Ziccardi L; Bersani G; Stifano G; Compagnone A; Falsini B
Rheumatol Int; 2010 Jan; 30(3):389-93. PubMed ID: 19424698
[TBL] [Abstract][Full Text] [Related]
12. A case of neonatal onset multisystem inflammatory disease supporting a role of interleukin-1β in moyamoya syndrome.
Wohlrab F; Bauknecht C; Meisel C; Dreier JP
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):e1-3. PubMed ID: 33109682
[No Abstract] [Full Text] [Related]
13. Resolution of femoral metaphyseal dysplasia in CINCA syndrome after long-term treatment with interleukin-1 blockade.
Rigante D; Manna R; Verrecchia E; Marrocco R; Leone A
Clin Rheumatol; 2018 Jul; 37(7):2007-2009. PubMed ID: 29766377
[TBL] [Abstract][Full Text] [Related]
14. A somatic NLRP3 mutation as a cause of a sporadic case of chronic infantile neurologic, cutaneous, articular syndrome/neonatal-onset multisystem inflammatory disease: Novel evidence of the role of low-level mosaicism as the pathophysiologic mechanism underlying mendelian inherited diseases.
Aróstegui JI; Lopez Saldaña MD; Pascal M; Clemente D; Aymerich M; Balaguer F; Goel A; Fournier del Castillo C; Rius J; Plaza S; López Robledillo JC; Juan M; Ibañez M; Yagüe J
Arthritis Rheum; 2010 Apr; 62(4):1158-66. PubMed ID: 20131270
[TBL] [Abstract][Full Text] [Related]
15. [Significant effect of IL-1 receptor antagonist treatment in two patients who had CINCA syndrome with constant symptoms for 13 years].
Idorn L; Vissing NH; Jensen L; Herlin T
Ugeskr Laeger; 2012 May; 174(22):1537-8. PubMed ID: 22668652
[TBL] [Abstract][Full Text] [Related]
16. [Muckle-Wells syndrome caused by a new cryopyrin mutation: effective treatment with interleukin-1 antagonist].
Rameev VV; Kozlovskaia LV; Bogdanova MV
Ter Arkh; 2012; 84(6):53-9. PubMed ID: 22997920
[TBL] [Abstract][Full Text] [Related]
17. [Cutaneous neutrophils infiltrates. Case 8. CINCA/NOMID syndrome].
Fraitag S
Ann Pathol; 2011 Jun; 31(3):203-7. PubMed ID: 21737003
[No Abstract] [Full Text] [Related]
18. Twenty year follow up of a patient with a new de-novo NLRP3 mutation (S595G) and CINCA syndrome.
Kanariou M; Dracou C; Spanou K; Möller J; Rösen-Wolff A; Schuster V; Roesler J
Klin Padiatr; 2009; 221(6):379-81. PubMed ID: 19890791
[TBL] [Abstract][Full Text] [Related]
19. [Update in interleukin-1 inhibition].
de Boysson H
Rev Med Interne; 2012 Apr; 33(4):235-7. PubMed ID: 22360831
[No Abstract] [Full Text] [Related]
20. Necrotizing Funisitis as an Intrauterine manifestation of Cryopyrin-Associated Periodic Syndrome: a case report and review of the literature.
Yokoi K; Minamiguchi S; Honda Y; Kobayashi M; Kobayashi S; Nishikomori R
Pediatr Rheumatol Online J; 2021 May; 19(1):77. PubMed ID: 34059097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
